PharmAla Biotech Holdings Inc, a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is thrilled to formally announce the launch of the Phenesafe AI platform, an AI technology stack specifically designed to derive novel substituted phenethylamine molecules for patent and subsequent development..

PharmAla生物技术控股公司是一家专注于LaNeo™ MDMA及MDMA新型衍生物（MDXX类分子）研究、开发和生产的生物技术公司，正式宣布推出Phenesafe AI平台，该平台是一个专为推导新型取代苯乙胺分子以申请专利并进行后续开发而设计的人工智能技术堆栈。

“Over the past year, our R&D team has been working towards the goal of creating a drug discovery platform which can be used to Identify additional molecules in the MDXX class. Our deeply held belief at PharmAla is that the MDXX class represents significant potential for patient treatment in a number of psychiatric and neurological indications,” said Nicholas Kadysh, CEO, PharmAla Biotech.

“在过去的这一年，我们的研发团队一直致力于创建一个药物发现平台，该平台可以用于识别MDXX类别的其他分子。我们在PharmAla深信，MDXX类别在多种精神和神经疾病的治疗方面具有巨大的潜力，” PharmAla生物技术公司首席执行官Nicholas Kadysh表示。

“Continued development of these new molecules represents an important and ongoing part of our work at PharmAla. With Phenesafe we can work smarter and faster to develop valuable new products.”.

“这些新分子的持续开发是我们PharmAla工作的重要且持续进行的一部分。通过Phenesafe，我们可以更聪明、更快地开发有价值的新产品。”

Phenseafe AI represents a combination of tools, working in conjunction, including a QSAR model developed in collaboration with the University of Windsor through a grant by the Ontario Centres of Innovation, and specialized AI chemical pathway modelling tools. In combination, Phenesafe AI allows for the development, screening, and ultimately patenting of novel molecules in the broader MDXX class..

Phenseafe AI 代表了一系列工具的组合，这些工具协同工作，包括通过安大略创新中心资助、与温莎大学合作开发的 QSAR 模型，以及专门的 AI 化学路径建模工具。综合起来，Phenesafe AI 能够在更广泛的 MDXX 类别中进行新型分子的开发、筛选，并最终申请专利。

“Discovering a new molecule is much like building a new product. You have to properly identify targets – in our case, specific neurological receptors and transporters – and structure/function relationships. Then you need to screen those molecules to see how difficult they would be to make, because a patent on a molecule you can’t synthesize is worthless,” said Harpreet Kaur, VP of Research, PharmAla Biotech.

“发现一个新分子很像开发一个新产品。你必须正确识别目标——在我们的案例中，是特定的神经受体和转运蛋白——以及结构/功能关系。然后你需要筛选这些分子，看看它们的合成难度如何，因为一个无法合成的分子专利是没有价值的，” PharmAla Biotech 研发副总裁哈普雷特·考尔表示。

“All the while, you must continue to keep focus on your goals: indication, safety profile, and intended function. The development of Phenesafe AI will help us do all of these elements more quickly, and effectively.”.

“与此同时，你必须继续专注于你的目标：适应症、安全性概况和预期功能。Phenesafe AI的开发将帮助我们更快、更有效地完成所有这些要素。”

The development of Phenesafe AI is driven by PharmAla’s drug development philosophy:

Phenesafe AI 的开发是由 PharmAla 的药物开发理念驱动的：

About PharmAla

关于PharmAla

PharmAla Biotech Holdings Inc. is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class.

PharmAla生物技术控股公司是一家专注于MDXX类分子（包括MDMA）的研究、开发和制造的生物技术公司。PharmAla成立时设定了双重目标：缓解全球范围内通用型、临床级MDMA的短缺，以推动临床试验及在特定司法管辖区的商业销售，同时开发同类别中的新型药物。

PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla’s research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators..

PharmAla 是目前唯一一家在临床试验之外提供临床级 MDMA 用于患者治疗的公司。PharmAla 的研发部门已经完成了多项知识产权家族的概念验证研究，包括其主要候选药物 ALA-002。PharmAla 是一家“以监管为先”的组织，成立的原则是，在致幻剂行业中，只有与监管机构保持良好关系，才能取得真正的成功。

For more information, please contact:

如需更多信息，请联系：

Nicholas Kadysh

尼古拉斯·卡迪什

Chief Executive Officer

首席执行官

PharmAla Biotech Holdings Inc.

菲尔玛生物技术控股公司

Email: press@PharmAla.ca

电子邮件：press@PharmAla.ca

Phone: 1-855-444-6362

电话：1-855-444-6362

Website: www.PharmAla.ca

网站：www.PharmAla.ca

Source: globenewswire.com

来源：globenewswire.com